Vor Biopharma VOR 深 沪
等待开盘 10-31 09:30:00 美东时间
19.68
-1.230
-5.88%
华盛通- 最 高20.47
- 今 开19.98
- 成交量 75.96万股
- 最 低 19.3701
- 昨 收 20.91
- 总市值 11.64亿
- 52周最高 26.00
- 市盈率 静 --
- 换手率 1.28%
- 52周最低 6.50
- 委 比 65.29%
- 总股本 5916.23万
- 历史最高 1272.40
- 量 比 0.96
- 振 幅 5.26%
- 历史最低 2.622
- 每 手 1
- 风险率 4.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vor Biopharma收涨0.38%，成交额853.05万美元
10月27日，Vor Biopharma（VOR）收涨0.38%，报18.33美元，成交额853.05万美元，市值10.84亿美元。 行情数据 • 开盘价：1...
10-27 05:44
William Blair Initiates Coverage On Vor Biopharma with Outperform Rating
William Blair analyst Myles Minter initiates coverage on Vor Biopharma (NASDAQ:VOR) with a Outperform rating.
10-21 20:38
Vor Biopharma收跌6.77%，成交额1342.98万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:46
药物受理最新动态：Vor Biopharma Inc.泰它西普注射液进口申请获受理
国家药品监督管理局药品审评中心数据显示，2026年10月12日，Vor Biopharma Inc.的泰它西普注射液申请已获受理，受理号为JXSL260027...
10-12 17:15
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio granted stock options and RSUs to 9 new employees on October 1, 2026, totaling 59,250 shares and 12,550 RSUs under the 2023 Inducement Plan. The stock options have a 10-year term with an exercise price of $18.06 per share, vesting over four years, while RSUs vest quarterly over the same period. Both are subject to continued employment and the terms of the Inducement Plan.
10-05 22:00
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio granted stock options for 83,600 shares and RSUs for 17,900 shares to 6 new employees on September 1, 2026, under the 2023 Inducement Plan. The stock options have a 10-year term with an exercise price of $22.64 per share, vesting over four years. RSUs vest similarly, with 25% after one year and the rest over the next three years. Both are subject to continued employment and the terms of the Inducement Plan. Vor Bio focuses on advancing te...
09-04 20:05
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $27
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $18 to $27.
08-13 00:05
Vor Biopharma Q2 EPS $(1.16) Misses $(0.70) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.70) by 65.71 percent. This is a 99.54 percent increase over losses of $(251.24) per share from the same period last year.
08-11 21:36
美股周涨跌榜 | 航空环境周涨38%，获美国防部5亿美元反无人机大单；RKLB 80亿美元收购案引爆太空板块！卫讯公司周涨34%
ABVX暴涨近50%，核心在研药物取得积极进展；航空环境周涨38%，获美国防部5亿美元反无人机大单；RKLB 80亿美元收购案引爆太空板块！卫讯公司周涨34%>>
07-03 17:17
